Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06530030 · ClinicalTrials.gov registry record
Goal Attainment and Physical Activity in People With Hemophilia A
A clinical trial, sponsored by Sanofi.
- Terminated
- Registry status
- 3
- Enrollment target
NCT06530030: Clinical Trial study, sponsored by Sanofi.
NCT06530030 is a clinical trial that was terminated before completion, run by Sanofi. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06530030 was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
Primary Outcome
Reported as number of individual goals with a raw GAS score of 0, +1, or +2 divided by the total number of goals set
Interventions
- DRUG efanesoctocog alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2025-09-18 |
Why NCT06530030 stopped before completion
NCT06530030 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which efanesoctocog alfa is the first listed.
NCT06530030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06530030 about?
NCT06530030 is a clinical study titled "Goal Attainment and Physical Activity in People With Hemophilia A". This is a Phase 4, multi-center, observational study conducted in patients aged 12 to 50 years with moderate or severe hemophilia A who are newly starting prophylaxis with efa in the US and Japan. This study aims to enroll 35 patients.
What is the current status of trial NCT06530030?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2024-11-26. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT06530030?
The interventions under investigation include: efanesoctocog alfa (DRUG).
Who is sponsoring clinical trial NCT06530030?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI